Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15784058 | 1.00 | TDP1 (0.44) | TDP1IDO1CHEK1TTRHTT | |
| SCHEMBL13560482 | 1.00 | TDP1 (0.44) | TDP1IDO1CHEK1TTRHTT | |
| SCHEMBL29400313 | 0.91 | ALDH1A1 (0.48) | TDP1IDO1CHEK1ROCK2CSF1R | |
| SCHEMBL2277337 | 0.91 | ALDH1A1 (0.48) | TDP1IDO1CHEK1ROCK2CSF1R | |
| SCHEMBL15783957 | 0.91 | ALDH1A1 (0.48) | TDP1IDO1CHEK1ROCK2CSF1R | |
| SCHEMBL1361818 | 0.91 | ALDH1A1 (0.48) | TDP1IDO1CHEK1ROCK2CSF1R | |
| SCHEMBL29846133 | 0.91 | ALDH1A1 (0.48) | TDP1IDO1CHEK1ROCK2CSF1R | |
| SCHEMBL17156549 | 0.90 | BACE1 (0.46) | TDP1IDO1CHEK1HTTBACE1 | |
| SCHEMBL17156551 | 0.90 | BACE1 (0.46) | TDP1IDO1CHEK1HTTBACE1 | |
| SCHEMBL18423157 | 0.87 | TDP1 (0.40) | TDP1IDO1CHEK1ROCK2CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115703758-B | Compounds used as kinase inhibitors, preparation method and application thereof | 中国医学科学院药物研究所 | 2024-03-26 | — | — | CN | disclosed |
| EP-3710427-B1 | SYNTHESIS OF A 2-INDOLINONE DERIVATIVE KNOWN AS INTERMEDIATE FOR PREPARING NINTEDANIB | FERMION OY (FI) | 2023-03-08 | — | — | EP | disclosed |
| CN-115703758-A | Compound used as kinase inhibitor and preparation method and application thereof | 中国医学科学院药物研究所 | 2023-02-17 | — | — | CN | disclosed |
| CN-112430222-B | Amino intermediate refining method | 江苏豪森药业集团有限公司 | 2022-08-09 | — | — | CN | disclosed |
| US-11261158-B2 | Synthesis of 2-indolinone derivatives | FERMION OY (FI) | 2022-03-01 | — | — | US | disclosed |
| CN-110746378-B | Preparation method of amino intermediate | 江苏豪森药业集团有限公司 | 2021-11-05 | — | — | CN | disclosed |
| CN-111848490-B | Preparation method of high-purity ethanesulfonic acid nintedanib | 江西国药有限责任公司 | 2021-09-24 | — | — | CN | disclosed |
| CN-112430222-A | Amino intermediate refining method | 江苏豪森药业集团有限公司 | 2021-03-02 | — | — | CN | disclosed |
| EP-3747864-A1 | A METHOD FOR PREPARING METHYL (Z)-3-[[4-[METHYL[2-(4-METHYL-1-PIPERAZINYL)ACETYL]AMINO]PHENYL]AMINO]PHENYLMETHYLENE)-OXINDOLE-6-CARBOXYLATE (INTEDANIB, NINTEDANIB) | ZENTIVA, K.S. (CZ) | 2020-12-09 | — | — | EP | disclosed |
| CN-111848490-A | Preparation method of high-purity ethanesulfonic acid nintedanib | 江西国药有限责任公司 | 2020-10-30 | — | — | CN | disclosed |
| EP-3328831-B1 | A METHOD FOR PREPARING METHYL (Z)-3-[[4-[METHYL[2-(4-METHYL-1-PIPERAZINYL)ACETYL]AMINO]PHENYL]AMINO]PHENYLMETHYLENE)-OXINDOLE-6-CARBOXYLATE (INTEDANIB, NINTEDANIB) | ZENTIVA KS (CZ) | 2020-07-29 | — | — | EP | disclosed |
| CN-110746378-A | Preparation method of amino intermediate | 江苏豪森药业集团有限公司 | 2020-02-04 | — | — | CN | disclosed |
| EP-2930167-B1 | AN INDOLINONE DERIVATIVE AS TYROSINE KINASE INHIBITOR | KBP BIOSCIENCES CO LTD (CN) | 2018-11-21 | — | — | EP | disclosed |
| US-10125122-B2 | Method for preparing methyl (Z)-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene)oxindole-6-carboxylate (intedanib, nintedanib) | ZENTIVA K.S. (CZ) | 2018-11-13 | — | — | US | disclosed |
| US-20180215735-A1 | METHOD FOR PREPARING METHYL (Z)-3-[[4-[METHYL[2-(4-METHYL-1-PIPERAZINYL)ACETYL]AMINO]PHEHYL]AMINO]PHENYLMETHYLENE)-OXINDOLE-6-CARBOXYLATE (INTEDANIB, NINTEDANIB) | ZENTIVA K.S. (CZ) | 2018-08-02 | — | — | US | disclosed |
| EP-3328831-A1 | A METHOD FOR PREPARING METHYL (Z)-3-[[4-[METHYL[2-(4-METHYL-1-PIPERAZINYL)ACETYL]AMINO]PHENYL]AMINO]PHENYLMETHYLENE)-OXINDOLE-6-CARBOXYLATE (INTEDANIB, NINTEDANIB) | Zentiva, K.S. (CZ) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017016530-A1 | A METHOD FOR PREPARING METHYL (Z)-3-[[4-[METHYL[2-(4-METHYL-1-PIPERAZINYL)ACETYL] AMINO]PHENYL]AMINO]PHENYLMETHYLENE)-OXINDOLE-6-CARBOXYLATE (INTEDANIB, NINTEDANIB) | ZENTIVA, K.S. (CZ) | 2017-02-02 | — | — | WO | disclosed |
| EP-2930167-A1 | INDOLE FULL KETONE DERIVATIVE USED AS TYROSINE-KINASE INHIBITOR | KBP Biosciences Co., Ltd. (CN) | 2015-10-14 | — | — | EP | disclosed |
| US-8304541-B2 | Process for the manufacture of an indolinone derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-20100311985-A1 | INDOLINONE DERIVATIVES AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261158-B2 | Synthesis of 2-indolinone derivatives | AZI2, AANAT, IDO1 | TDP1 2346/4885IDO1 3/4885CHEK1 1568/4885 |
| US-20100311985-A1 | INDOLINONE DERIVATIVES AND PROCESS FOR THEIR MANUFACTURE | HTR3C, IDO1, IDO2 | TDP1 2154/4885IDO1 2/4885CHEK1 2452/4885 |
| US-20180215735-A1 | METHOD FOR PREPARING METHYL (Z)-3-[[4-[METHYL[2-(4-METHYL-1-PIPERAZINYL)ACETYL]AMINO]PHEHYL]AMINO]PHENYLMETHYLENE)-OXINDOLE-6-CARBOXYLATE (INTEDANIB, NINTEDANIB) | ALK, ACVR2B, ACVR1B | TDP1 1382/4885IDO1 31/4885CHEK1 2484/4885 |
| US-10125122-B2 | Method for preparing methyl (Z)-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene)oxindole-6-carboxylate (intedanib, nintedanib) | ALK, ACVR2B, NAT1 | TDP1 1765/4885IDO1 15/4885CHEK1 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.